Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE0010 add-on to sulfonylurea in type 2 diabetes
2007-005881-11Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing AVE0010 add-on with Placebo add-on (2 arms). Primary endpoint: Change in HbA1c at 24 weeks. Started Apr 2008; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-005881-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005881-11.